- Home
- MARPS vs VRAX Comparison
MARPS vs VRAX Comparison
Compare MARPS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | VRAX |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 1.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MARPS | VRAX |
|---|---|---|
| Price | $5.75 | $0.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 100.4K | ★ 148.8K |
| Earning Date | 02-13-2026 | 03-10-2026 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $0.17 |
| 52 Week High | $6.49 | $1.34 |
Technical Indicators
Market Signals| Indicator | MARPS | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 33.39 |
| Support Level | $4.23 | N/A |
| Resistance Level | $6.49 | $0.25 |
| Average True Range (ATR) | 0.33 | 0.02 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 88.80 | 12.37 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.